Tocagen Inc.: Clinical Trials

8 trials sponsored by Tocagen Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 2 withdrawn. 7 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 17Completed 3, Terminated 2, Withdrawn 2
Phase 21Terminated 1
Phase 31Terminated 1

Follow Tocagen Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
Toca 511, Toca FC (extended-release formulation of flucytosine) - Bladder Cancer
Phase 1WithdrawnTocagen Inc.2019-12-012020-03-30
A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
Toca 511, Toca FC - Newly Diagnosed High Grade Glioma (HGG)
Phase 1WithdrawnTocagen Inc.2017-01-012020-03-30
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Toca 511, Toca FC - Colorectal Cancer, Triple Negative Breast Cancer
Phase 1TerminatedTocagen Inc.212016-07-012020-02-07
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 2 / Phase 3TerminatedTocagen Inc.4032015-11-302020-02-07
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Toca 511, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1CompletedTocagen Inc.172014-02-012018-05-21
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Toca 511 vector, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1CompletedTocagen Inc.582012-02-012018-05-21
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine - Glioblastoma Multiforme, Astrocytoma
Phase 1TerminatedTocagen Inc.652011-02-012020-03-30
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
Toca 511 vector, Toca FC - Glioblastoma, Anaplastic Astrocytoma
Phase 1CompletedTocagen Inc.542010-07-012018-05-21

Conditions studied

Astrocytoma (6)  ·  Glioblastoma (6)  ·  Brain Neoplasms (4)  ·  Glioma (4)  ·  Oligodendroglioma (4)  ·  Urinary Bladder Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Non-Muscle Invasive Bladder Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Recurrence (1)

Interventions

Flucytosine (8)  ·  vocimagene amiretrorepvec (7)  ·  Bevacizumab (1)  ·  Genetic Engineering (1)  ·  Genetic Therapy (1)  ·  Lomustine (1)  ·  Temozolomide (1)

Countries

United States (6)  ·  Canada (1)  ·  Israel (1)  ·  South Korea (1)

Top investigators

Asha Das, MD (4)  ·  Jaime R Merchan, MD (1)  ·  Manish Aghi, MD, NS (1)  ·  Michael Vogelbaum, MD, PhD, NS (1)  ·  Steven Kalkanis, MD (1)  ·  Timothy Cloughesy, MD (1)  ·  Timothy Cloughesy, MD, NO (1)

Results publications

PMID 27252174, PMID 29322091, PMID 29735994, PMID 29762717, PMID 33119048